BioPharma Dive

Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...
The Silicon Review

Eli Lilly Acquires Ventyx for $1.2B in Oral Immunology Bet

Eli Lilly buys Ventyx Biosciences for $1.2B, targeting oral NLRP3 inflammasome inhibitors to expand its immunology pipeline ...
WFYI

Indiana sues Eli Lilly alleging insulin price-fixing scheme

The lawsuit alleges insulin can cost Eli Lilly just a few dollars to produce, while some consumers are charged hundreds of ...
WBIW

Attorney General Todd Rokita fights to lower healthcare costs for Hoosiers with new lawsuit against Eli Lilly

Attorney General Todd Rokita is intensifying his efforts to lower insulin prices and improve healthcare affordability for ...

Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition

Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.

Eli Lilly stock hits all-time high of 1113.03 USD

Eli Lilly stock reached an all-time high of 1113.03 USD, marking a significant milestone for the pharmaceutical giant. This achievement reflects a robust 41.51% increase over the past year, ...

Indiana attorney general sues Eli Lilly over insulin pricing

Indiana Attorney General Todd Rokita on Monday announced a new lawsuit against Indianapolis-based drug maker Eli Lilly and Co ...

Should you buy Eli Lilly before it reaches $1 trillion in market value?

Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent ...